Involvement of HMGB1 in Resistance to Tumor Vessel-Targeted, Monoclonal Antibody-Based Immunotherapy
High mobility group box 1 (HMGB1) is a member of the “danger associated molecular patterns” (DAMPs) than can localize in various compartments of the cell (from the nucleus to the cell surface) and subserve different functions accordingly. HMGB1 is implicated in maintenance of genomic stability, auto...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2016/3142365 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832545985832681472 |
|---|---|
| author | Vito Pistoia Annalisa Pezzolo |
| author_facet | Vito Pistoia Annalisa Pezzolo |
| author_sort | Vito Pistoia |
| collection | DOAJ |
| description | High mobility group box 1 (HMGB1) is a member of the “danger associated molecular patterns” (DAMPs) than can localize in various compartments of the cell (from the nucleus to the cell surface) and subserve different functions accordingly. HMGB1 is implicated in maintenance of genomic stability, autophagy, immune regulation, and tumor growth. HMGB1-induced autophagy promotes tumor resistance to chemotherapy, as shown in different models of malignancy, for example, osteosarcoma, leukemia, and gastric cancer. To the best of our knowledge, there is virtually no information on the relationships between HMGB1 and resistance to immunotherapy. A recent study from our group has shed new light on this latter issue. We have demonstrated that targeting of tumor-derived endothelial cells with an anti-human CD31 monoclonal antibody in a human neuroblastoma model was unsuccessful due to a complex chain of events involving the participation of HMGB1. These results are discussed in detail since they provide the first evidence for a role of HMGB1 in resistance of tumor cells to monoclonal antibody-based immunotherapy. |
| format | Article |
| id | doaj-art-50cc0a33524a4ed99c1ecb1f7d301109 |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-50cc0a33524a4ed99c1ecb1f7d3011092025-02-03T07:24:07ZengWileyJournal of Immunology Research2314-88612314-71562016-01-01201610.1155/2016/31423653142365Involvement of HMGB1 in Resistance to Tumor Vessel-Targeted, Monoclonal Antibody-Based ImmunotherapyVito Pistoia0Annalisa Pezzolo1Laboratorio di Oncologia, Istituto Giannina Gaslini, 16147 Genova, ItalyLaboratorio di Oncologia, Istituto Giannina Gaslini, 16147 Genova, ItalyHigh mobility group box 1 (HMGB1) is a member of the “danger associated molecular patterns” (DAMPs) than can localize in various compartments of the cell (from the nucleus to the cell surface) and subserve different functions accordingly. HMGB1 is implicated in maintenance of genomic stability, autophagy, immune regulation, and tumor growth. HMGB1-induced autophagy promotes tumor resistance to chemotherapy, as shown in different models of malignancy, for example, osteosarcoma, leukemia, and gastric cancer. To the best of our knowledge, there is virtually no information on the relationships between HMGB1 and resistance to immunotherapy. A recent study from our group has shed new light on this latter issue. We have demonstrated that targeting of tumor-derived endothelial cells with an anti-human CD31 monoclonal antibody in a human neuroblastoma model was unsuccessful due to a complex chain of events involving the participation of HMGB1. These results are discussed in detail since they provide the first evidence for a role of HMGB1 in resistance of tumor cells to monoclonal antibody-based immunotherapy.http://dx.doi.org/10.1155/2016/3142365 |
| spellingShingle | Vito Pistoia Annalisa Pezzolo Involvement of HMGB1 in Resistance to Tumor Vessel-Targeted, Monoclonal Antibody-Based Immunotherapy Journal of Immunology Research |
| title | Involvement of HMGB1 in Resistance to Tumor Vessel-Targeted, Monoclonal Antibody-Based Immunotherapy |
| title_full | Involvement of HMGB1 in Resistance to Tumor Vessel-Targeted, Monoclonal Antibody-Based Immunotherapy |
| title_fullStr | Involvement of HMGB1 in Resistance to Tumor Vessel-Targeted, Monoclonal Antibody-Based Immunotherapy |
| title_full_unstemmed | Involvement of HMGB1 in Resistance to Tumor Vessel-Targeted, Monoclonal Antibody-Based Immunotherapy |
| title_short | Involvement of HMGB1 in Resistance to Tumor Vessel-Targeted, Monoclonal Antibody-Based Immunotherapy |
| title_sort | involvement of hmgb1 in resistance to tumor vessel targeted monoclonal antibody based immunotherapy |
| url | http://dx.doi.org/10.1155/2016/3142365 |
| work_keys_str_mv | AT vitopistoia involvementofhmgb1inresistancetotumorvesseltargetedmonoclonalantibodybasedimmunotherapy AT annalisapezzolo involvementofhmgb1inresistancetotumorvesseltargetedmonoclonalantibodybasedimmunotherapy |